End Stage Liver Disease Flashcards

1
Q

What are the two types of damage seen in decompensated cirrhosis?

A

hepatocellular dysfunction

complications of portal hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List clinical signs of hepatocellular dysfunction

A
Jaundice, cholestasis
fat soluble vitamin deficiency
coagulopathy- bleeding and bruising
hepatic encephalopathy
hypoalbuminemia
hormonal deficiencies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List complications of portal hypertension

A
Ascites
Spontaneous Bacterial Peritonitis
Hepatorenal Syndrome
Variceal Hemorrhage
Hepatic Encephalopathy
Pulmonary Complications of Cirrhosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

List pre hepatic causes of portal hypertension

A

portal vein thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List post hepatic causes of portal hypertension

A

IVC or hepatic vein occlusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

List intrahepatic portal hypertension

A
  • post sinusoidal
  • sinusoidal (cirrhosis)
  • pre sinusoidal (schistosomiasis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

In patients with cirrhosis, portal hypertension leads to shunting and increased capillary hydrostatic pressure, with ______ fluid shift into the peritoneal cavity

A

transudative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

The combination of shunting and hepatocellular dysfunction in cirrhosis leads to decreased clearance of endogenous vasodilators such as ______

A

nitric oxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Splanchnic ______ leads to increased portal inflow, further worsening portal hypertension

A

vasodilation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Splanchnic vasodilation leads to a decrease in the_______, with subsequent reduction in vascular tone and blood pressure causing activation of the RAAS and SNS systems

A

effective circulating volume (ECV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Activation of RAAS and SNS, total body fluid increases, and portal hypertension eventually overwhelm the lymphatics of the liver and splanchnic system, leading to ______ formation

A

ascites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

________ leads to the complication of hepatorenal syndrome

A

Renal vasoconstriction (in response to perceived low circulating volume)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the SAAG?

A

Serum to ascites albumin gradient
= serum albumin- ascites albumin
if > 1.1 then ascites is due to portal hypertension
if < 1.1 then ascites is due to malignancy, TB, bile leak, SLE, etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

__________ can be caused by intense renal vasoconstriction in the setting of portal hypertension

A

acute kidney injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List common precipitants of hepatorenal syndrome

A

infection esp spontaneous bacterial peritonitis
diuretics
paracentesis
lactulos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How can hepatorenal syndrome be distinguished from pre-renal failure

A

Unlike pre-renal failure, HRS does not respond to volume expansion

17
Q

Describe the formation of varices in portal hypertension

A

Collateral vessels from, when portal pressure increases, these collaterals dilate and are called varices.

18
Q

Describe the pathophysiology of hepatic encephalopathy

A
  • decreased hepatocellular function- unable to eliminate toxins that cause hepatic encephalopathy
  • shunt: portal blood is shunted away from the liver, so liver is not able to detoxify substances
  • ammonia and other toxins disturbe neurotransmission and lead to osmotic swelling of astrocytes
19
Q

Splenomegaly leads to ______, which causes consumption and sequestration, initially of platelets leading to thrombocytopenia

A

hypersplenism

20
Q

List endocrine features of hepatocellular insufficiency

A
  • androgenic failure and feminization
  • amenorrhoea, anovulation
  • spider angiomata
  • palmar erythema
21
Q

Describe the pathology of bone disease in chronic liver disease

A

immobility and lack of sunlight

disordered hepatic metabolism of vitamin D

22
Q

List infections that people with cirrhosis are at risk for

A

pneumonia
sepsis secondary to UTI
TB
SBP

23
Q

_______ is a bacterial infection of ascites fluid in a patient with liver disease

A

spontaneous bacterial peritonitis

24
Q

How is SBP diagnosed?

A

> 250 PMNs per ml ascitic fluid

25
What malignancies are more common in people with cirrhosis
HCC hepatoma cholangiocarcinoma
26
What are causes of death for people with end stage liver disease?
Acute gastrointestinal hemorrhage Bacterial infection Multisystem failure, particularly the combination of hepatic and renal failure
27
Describe therapy for acute variceal bleeding
resuscitation- RBCs, FFP vasoactive medications- octreonide causes splanchnic vasoconstriction and reduces portal flow antibiotics PPIs emergency endoscopy- band ligation or sclerosants if band ligation is not possible
28
_______ causes splanchnic vasoconstriction and reduces portal blood flow
octreonide
29
For patients that fail endoscopic control of variceal hemorrhage_________ can be placed
portosystemic shunts | ex TIPS procedure
30
What are measures used to reduce the risk of rebleeding in patients treated for variceal hemorrhage?
beta blockers- induce splanchnic vasoconstriction | TIPS if refractory bleeding
31
What measures are used to treat hepatorenal syndrome, ascites, and SBP
``` low salt diet diuretics esp loop and spironolactone paracentesis + albumin TIPS IV antibiotics + albumin ```
32
Giving IV albumin along with antibiotics in SBP can reduce mortality and the risk of developing _________
hepatorenal syndrome
33
How is hepatic encephalopathy treated?
avoid or remove precipitants- diuretics, benzos, opioids lactulose - traps NH3 in form of NH4 rifaximin